---
document_datetime: 2023-12-22 13:09:37
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/natpar-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: natpar-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.6353238
conversion_datetime: 2025-12-27 16:21:27.977644
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Natpar

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| N/0055               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 20/12/2023                          |                                             | PL                               |                                   |
| PSUSA/10591 /202304  | Periodic Safety Update EU Single assessment - parathyroid hormone                                | 30/11/2023                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0050             | Submission of the final report from study SHP634- 401 (BALANCE). This is a phase 3b-4, randomized, double-blind, placebo controlled, adaptive study to evaluate symptom improvement and metabolic control among adult subjects with symptomatic hypoparathyroidism treated with recombinant human parathyroid hormone [rhPTH(1-84)]. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | 20/07/2023   | n/a   |                                  |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------|-----------------------------------|
| IAIN/0052/G         | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                             | 01/06/2023   |       | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/10591 /202210 | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/05/2023   | n/a   |                                  | PRAC Recommendation - maintenance |
| IB/0051             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                       | 26/04/2023   |       | SmPC, Annex II and PL            |                                   |
| II/0042             | To update Annex II of the Product Information and the RMP for Natpar to version 3.6 to change the due date for study SHP634-403 listed as a Specific Obligation in the Annex II of the Product Information from '30 June 2023' to '30 June 2025'.                                                                                                                                                                                                                                    | 30/03/2023   |       | Annex II                         |                                   |

<div style=\"page-break-after: always\"></div>

|           | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                               |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0046    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 15/12/2022 | 06/03/2023 |                                  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Natpar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0047/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products | 26/01/2023 |            | SmPC, Annex II, Labelling and PL | The SmPC section 6.6, Labelling and Package Leaflet have been updated as follows: Removal of the references and text related to the Ypsomed Clickfine pen needle approved with variation II/33/G (see above). Annex II have been updated as follows: Removal of the condition related to bi-layer bromobutyl rubber septum and Ypsomed Clickfine pen needle that had been approved with variation II/33/G (see above).                                                           |

<div style=\"page-break-after: always\"></div>

| N/0048              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/01/2023   |            | PL                               |                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10591 /202204 | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 01/12/2022   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                  |
| IB/0044             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 25/07/2022   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                    |
| II/0033/G           | This was an application for a group of variations. B.IV.1.a.3 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Spacer device for metered dose inhalers or other device which may have a significant impact on the delivery of the AS B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol | 21/07/2022   | 06/03/2023 | SmPC, Annex II, Labelling and PL | The SmPC section 6.6 and the labelling have been updated to refer to the Ypsomed Clickfine pen needles. Annex II section D 'obligation to conduct post-authorisation measures' has been updated to reflect the above- mentioned condition. The package leaflet has been updated to refer to the Ypsomed Clickfine pen needles and update the instructions for use. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10591 /202110   | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                            | 10/06/2022   | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0043               | B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test    | 09/06/2022   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0041               | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 20/05/2022   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0040               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                | 13/04/2022   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0034                | Renewal of the marketing authorisation.                                                                                                      | 27/01/2022   | 22/03/2022 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Natpar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0035               | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                        | 10/03/2022   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0038             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                           | 10/02/2022   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| II/0030/G           | This was an application for a group of variations.                                                                                                                                                                                     | 16/12/2021   | n/a        |                        | n/a                               |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IAIN/0036           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 14/12/2021   | 22/03/2022 | Annex II and PL        |                                   |
| PSUSA/10591 /202104 | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                      | 02/12/2021   | n/a        |                        | PRAC Recommendation - maintenance |
| T/0032              | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 13/09/2021   | 19/10/2021 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10591 /202010   | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 10/06/2021   | n/a        |                        | PRAC Recommendation - maintenance                                                                     |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------|
| R/0027                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/02/2021   | 15/04/2021 |                        |                                                                                                       |
| II/0026               | Submission of the final results of study PAR-C10- 008; a long-term open-label study investigating the safety and tolerability of a rhPTH[1-84] for the treatment of adults with hypoparathyroidism - a clinical extension study (RACE). Update of SmPC section 5.1 to reflect 72 months data from the study. Update of the RMP (version 3.1) with the completed study results, to remove this study as an additional pharmacovigilance activity and to align with the GVP module V Rev 2. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 11/03/2021   | 19/10/2021 | SmPC                   | The study results show durability of the physiological effects of Natpar over 72 months of treatment. |
| PSUSA/10591 /202004   | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/11/2020   | n/a        |                        | PRAC Recommendation - maintenance                                                                     |
| PSUSA/10591 /201910   | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/05/2020   | n/a        |                        | PRAC Recommendation - maintenance                                                                     |
| IB/0024/G             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.IV.1.z - Change of a measuring or administration                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/04/2020   | 15/04/2021 | SmPC, Labelling and PL |                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | device - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0022    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/02/2020 | 17/04/2020 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Natpar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0020/G | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study | 20/02/2020 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0021   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                          | 14/11/2019 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| PSUSA/10591 /201904   | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                          | 31/10/2019   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013/G             | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is an integrated part of the primary packaging | 25/07/2019   | 17/04/2020 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0018/G             | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                          | 18/07/2019   | 17/04/2020 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/10591 /201810   | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                          | 16/05/2019   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                   |
| R/0016                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                    | 28/02/2019   | 29/04/2019 |                                  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Natpar, subject to the |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                            |            |            |                                  | Specific Obligations and Conditions as laid down in Annex II to the opinion.                                                               |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| II/0015             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol | 17/01/2019 | n/a        |                                  |                                                                                                                                            |
| PSUSA/10591 /201804 | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                          | 15/11/2018 | 15/01/2019 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10591/201804. |
| IB/0012             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                 | 09/11/2018 | n/a        |                                  |                                                                                                                                            |
| IAIN/0014/G         | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release   | 24/09/2018 | 15/01/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                            |
| N/0011              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                           | 22/08/2018 | 15/01/2019 | PL                               |                                                                                                                                            |
| IB/0009/G           | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                             | 11/07/2018 | n/a        |                                  |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition or replacement of an in-process test as a result of a safety or quality issue B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10591 /201710 | Periodic Safety Update EU Single assessment - parathyroid hormone                                                                                                                                                                                                                                | 17/05/2018 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| R/0007              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                          | 22/02/2018 | 19/04/2018 |      | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Natpar, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.                                                       |
| II/0005             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                | 25/01/2018 | 19/04/2018 | SmPC | The Marketing Authorisation Holder provided interim results for Study 2 (PAR-C10-008; RACE); a long-term, open-label extension study of daily subcutaneous dosing of Natpar in hypoparathyroidism patients who completed prior studies with Natpar. A total of 49 patients were enrolled in the study. Patients received doses of 25 micrograms, 50 micrograms, 75 micrograms or 100 micrograms/day for up to approximately 60 months (mean 1161 days, range 41 to 1820 days). The results demonstrate durability of the physiological |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     | effects of Natpar over 60 months including maintenance of mean albumin-corrected serum calcium levels (n=49, 2.11 ±19 mmol/L), a decrease from baseline in urinary calcium excretion (n= 47, 2.23 ± 5.9 mmol/24 h), a decrease in serum phosphate (n= 49, 0.29 ±28 mmol/L) and the maintenance of normal calcium phosphate product (n=49, <4.4mmol2/L2).   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004/G | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 14/12/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                            |
| II/0006   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 30/11/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0001/G   | This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a medicinal product                                                                            | 10/08/2017   | n/a        |                 | biological/immunological   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|----------------------------|
| IB/0002     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                             | 08/08/2017   | n/a        |                 |                            |
| IAIN/0003/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 14/06/2017   | 19/04/2018 | Annex II and PL |                            |